Literature DB >> 16363617

Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure.

Takanori Arimoto1, Yasuchika Takeishi, Takeshi Niizeki, Yo Koyama, Hidenobu Okuyama, Naoki Nozaki, Osamu Hirono, Yuichi Tsunoda, Takehiko Miyashita, Tetsuro Shishido, Akio Okada, Kazuei Takahashi, Isao Kubota.   

Abstract

UNLABELLED: Iodine-123-metaiodobenzylguanidine (123I-MIBG) has been used to assess the integrity and function of the cardiac sympathetic nervous system in patients with heart failure. Heart-type fatty acid binding protein (H-FABP) is released into the circulation when the myocardium is injured, and H-FABP has been recently used as a novel marker for the diagnosis of ongoing myocardial damage.
OBJECTIVE: The aim of the present study was to compare cardiac sympathetic nervous activity assessed by 123I-MIBG imaging with serum levels of H-FABP in patients with heart failure.
METHODS: Fifty patients with chronic heart failure were studied. 123I-MIBG imaging was carried out at 30 min (early) and 240 min (delayed) after the tracer injection. We measured serum levels of H-FABP using a sandwich enzyme linked immunosorbent assay.
RESULTS: Heart to mediastinum (H/M) ratios of 123I-MIBG decreased and washout rate increased with higher New York Heart Association (NYHA) functional class. H-FABP, norepinephrine and brain natriuretic peptide (BNP) levels increased as the severity of NYHA class advanced. Delayed H/M ratio was significantly correlated with H-FABP (r = -0.296, p = 0.029) and BNP (r = -0.335, p = 0.0213). Myocardial washout rate of 123I-MIBG was also correlated with H-FABP (r = 0.469, p < 0.001), norepinephrine (r = 0.433, p = 0.005), and BNP (r = 0.465, p = 0.001).
CONCLUSIONS: These data suggest that cardiac sympathetic nervous activation was associated with ongoing cardiomyocyte damage characterized by an elevated serum level of H-FABP in patients with heart failure. 123I-MIBG imaging is an appropriate approach to evaluate non-invasively not only cardiac sympathetic nervous activity, but also latent ongoing myocardial damage in the failing heart.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16363617     DOI: 10.1007/bf02985045

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  6 in total

1.  Late cardiac effect of radiation therapy on a young woman with mediastinal Hodgkin's lymphoma.

Authors:  Ken Kodama; Hiroshi Takami; Masahiro Izumi; Yoshimune Hiramoto; Kyotaro Yoshida; Kiyonori Nishioka; Masahiko Higashiyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-23

Review 2.  Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.

Authors:  Ronny S Jiji; Christopher M Kramer; Michael Salerno
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

Review 3.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

Review 4.  Neuronal imaging using SPECT.

Authors:  Shohei Yamashina; Jun-ichi Yamazaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

5.  Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study.

Authors:  Taro Narumi; Tetsuro Shishido; Nobuyuki Kiribayashi; Shinpei Kadowaki; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Takehiko Miyashita; Takuya Miyamoto; Tetsu Watanabe; Yoko Shibata; Tsuneo Konta; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Exp Diabetes Res       Date:  2012-10-10

6.  Cardiac I123-MIBG correlates better than ejection fraction with symptoms severity in systolic heart failure.

Authors:  Sandra M Miranda; Samuel D Moscavitch; Larissa R Carestiato; Renata M Felix; Ronaldo C Rodrigues; Leandro R Messias; Jader C Azevedo; Antonio Cláudio L Nóbrega; Evandro Tinoco Mesquita; Claudio Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2013-07       Impact factor: 2.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.